Goldman Sachs Group Inc Celldex Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 727,504 shares of CLDX stock, worth $20.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

727,504

Previous 696,007 4.53%

Holding current value

$20.1 Million

Previous $12.6 Million 17.19%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$15.13 - $21.65 $476,549 - $681,910	31,497 Added 4.53%	727,504 $14.8 Million
Q1 2025 May 09, 2025	SELL	$18.15 - $27.6 $9.19 Million - $14 Million	-506,446 Reduced 42.12%	696,007 $12.6 Million
Q4 2024 Feb 11, 2025	SELL	$23.31 - $32.4 $14.8 Million - $20.5 Million	-633,390 Reduced 34.5%	1,202,453 $30.4 Million
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $30.8 Million - $42.9 Million	961,650 Added 110.0%	1,835,843 $62.4 Million
Q2 2024 Aug 13, 2024	BUY	$32.76 - $42.56 $10.1 Million - $13.2 Million	309,390 Added 54.78%	874,193 $32.4 Million
Q1 2024 May 15, 2024	BUY	$35.22 - $51.88 $4.47 Million - $6.59 Million	127,044 Added 29.02%	564,803 $23.7 Million
Q4 2023 Feb 13, 2024	BUY	$22.61 - $40.65 $586,164 - $1.05 Million	25,925 Added 6.3%	437,759 $17.4 Million
Q3 2023 May 14, 2024	SELL	$25.45 - $37.46 $659,791 - $971,150	-25,925 Reduced 5.92%	411,834 $11.3 Million
Q3 2023 Nov 14, 2023	SELL	$25.45 - $37.46 $790,629 - $1.16 Million	-31,066 Reduced 7.01%	411,834 $11.3 Million
Q2 2023 May 14, 2024	BUY	$30.29 - $38.28 $2.51 Million - $3.17 Million	82,727 Added 22.97%	442,900 $15 Million
Q2 2023 Aug 14, 2023	BUY	$30.29 - $38.28 $2.51 Million - $3.17 Million	82,727 Added 22.97%	442,900 $15 Million
Q1 2023 May 14, 2024	SELL	$34.78 - $47.43 $3.11 Million - $4.24 Million	-89,411 Reduced 19.89%	360,173 $13 Million
Q1 2023 May 11, 2023	SELL	$34.78 - $47.43 $3.11 Million - $4.24 Million	-89,411 Reduced 19.89%	360,173 $13 Million
Q4 2022 May 14, 2024	SELL	$27.78 - $45.38 $5.97 Million - $9.75 Million	-214,847 Reduced 32.34%	449,584 $20 Million
Q4 2022 Feb 13, 2023	SELL	$27.78 - $45.38 $5.97 Million - $9.75 Million	-214,847 Reduced 32.34%	449,584 $20 Million
Q3 2022 May 14, 2024	BUY	$22.7 - $37.57 $5.1 Million - $8.44 Million	224,719 Added 51.11%	664,431 $18.7 Million
Q3 2022 Nov 10, 2022	BUY	$22.7 - $37.57 $5.1 Million - $8.44 Million	224,719 Added 51.11%	664,431 $18.7 Million
Q2 2022 May 14, 2024	BUY	$20.5 - $37.33 $40,036 - $72,905	1,953 Added 0.45%	439,712 $11.9 Million
Q2 2022 Aug 15, 2022	BUY	$20.5 - $37.33 $2.79 Million - $5.09 Million	136,293 Added 44.92%	439,712 $11.9 Million
Q1 2022 May 16, 2022	BUY	$27.64 - $39.32 $1.36 Million - $1.93 Million	49,205 Added 19.36%	303,419 $10.3 Million
Q4 2021 Feb 14, 2022	SELL	$35.68 - $56.27 $1.91 Million - $3.01 Million	-53,465 Reduced 17.38%	254,214 $9.82 Million
Q3 2021 Nov 10, 2021	BUY	$28.95 - $55.99 $8.91 Million - $17.2 Million	307,679 New	307,679 $16.6 Million

Others Institutions Holding CLDX

# of Institutions

200

Shares Held

68.3M

Call Options Held

219K

Put Options Held

238K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.29B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Celldex Therapeutics, Inc. Transaction History